A Phase 2 interventional study of 5x5cm bupivacaine collagen sponges in Hernia and Postoperative Pain, sponsored by Innocoll. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-04.
Sponsored by Innocoll · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing bupivacaine in Hernia — 1 open to participants now, 1 under way, none of them phase 3. Bupivacaine · Hernia.
Among the 12 studies testing bupivacaine in Hernia, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 2, and was the 3rd registered.
257 studies on the registry are indexed under Hernia; 37 are open to participants now.
Browse Hernia studies →1 of the 12 studies testing bupivacaine in Hernia is open now. Recruiting first, the newest first:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 24 Hernia studies recruiting now, 17 (71%) set no upper age limit and 2 (8%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 80 across 167 interventional studies indexed under Hernia.
Median enrollment 89 across the 12 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 7 most frequent:
Innocoll is the lead sponsor of 21 studies on the registry; none are open to participants now.
Innocoll has 2 studies filed under Hernia — fewer than ten, so there is no comparison to draw.
1 of the studies testing bupivacaine in Hernia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07564180Amr mohamedSpinal Anesthesia With Bupivacaine Versus Prilocaine on Postoperative Shivering After Inguinal Hernia Repair | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing bupivacaine in Hernia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess pain intensity for the first 72 hrs after aggravated movement (cough) following Laparoscopic Inguinal or Umbilical Herniorrhaphy.
Inguinal herniorrhaphy is a common surgery; approximately 2,800 per million people in the United States (US) undergo the procedure annually.Common surgical methods of herniorrhaphy include open and laparoscopic placement of synthetic mesh. Studies have shown that the use of synthetic mesh greatly reduces the risk of hernia recurrence regardless of the method used for its placement. Furthermore, utilizing the laparoscopic approach for umbilical hernia repair, specifically with the use of mesh, may also reduce the risk of infection.
Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes from cow tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery.
This open-label study will assess pain intensity after surgery in patients who receive the CollaRx Bupivacaine implant as well as determine the feasibility of the use of the laparoscope for sponge placement in laparoscopic hernia repair.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
bupivacaine collagen sponges
Drug: 5x5cm bupivacaine collagen sponges
Also known as: Bupivacaine collagen implant
Total Use of Opioid Analgesia - Morphine Equivalence (mg)
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
Time frame: 0 to 24 hours after surgery
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
Time frame: 25-48 hours
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
Time frame: 49-72 Hours
Total Use of Opioid Rescue Analgesia Morphine Equivalence (mg)
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
Time frame: 0-48 hours)
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
Time frame: 0-72 hours
| Milestone | Drug: Bupivacaine Collagen Sponge |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
| Morphine Equivalence (mg) | Bupivacaine Collagen Sponge |
|---|---|
| Total Use of Opioid Analgesia - Morphine Equivalence (mg) | 19.3 ± 15.5 |
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
| Morphine Equivalence (mg) | Bupivacaine Collagen Sponge |
|---|---|
| Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg) | 5.3 ± 7.3 |
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
| Morphine Equivalence (mg) | Bupivacaine Collagen Sponge |
|---|---|
| Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg) | 2.0 ± 3.3 |
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
| Morphine Equivalence (mg) | Bupivacaine Collagen Sponge |
|---|---|
| Total Use of Opioid Rescue Analgesia Morphine Equivalence (mg) | 24.6 ± 21.8 |
Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.
| Morphine Equivalence (mg) | Bupivacaine Collagen Sponge |
|---|---|
| Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg) | 26.6 ± 23.2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Drug: Bupivacaine Collagen Sponge | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| Event | Drug: Bupivacaine Collagen Sponge |
|---|---|
| Sleep ApneaRespiratory, thoracic and mediastinal disorders | 1/10 |
| Event | Drug: Bupivacaine Collagen Sponge |
|---|---|
| HeadacheNervous system disorders | 2/10 |
| NauseaGastrointestinal disorders | 2/10 |
| HypoxemiaRespiratory, thoracic and mediastinal disorders | 2/10 |
| ParesthesiaNervous system disorders | 1/10 |
| ItchingSkin and subcutaneous tissue disorders | 1/10 |
| ConstipationGastrointestinal disorders | 1/10 |
| DiarrheaGastrointestinal disorders | 1/10 |
| VomitingGastrointestinal disorders | 1/10 |
| Scrotal SwellingReproductive system and breast disorders | 1/10 |
| AnxietyPsychiatric disorders | 1/10 |
| Age, Continuous(years) | Drug: Bupivacaine Collagen Sponge |
|---|---|
| Mean | 48 ± 9.76 |
| Sex: Female, Male(Participants) | Drug: Bupivacaine Collagen Sponge |
|---|---|
| Female | 0 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Drug: Bupivacaine Collagen Sponge |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Drug: Bupivacaine Collagen Sponge |
|---|---|
| United States | 10 |
Ran from Mar 2011 to primary completion in Jun 2011, 2 months.
Results were first posted in Nov 2020, 9 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine